The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The biopharmaceutical company AstraZeneca announced it will $50 billion into the United States, with plans to open several ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump ...

The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.

AstraZeneca said the “cornerstone” of the commitment would be a new weight management production facility for its oral GLP-1 ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...